MiniMed Group is trading 4.8% up at $16.88 in pre-market, extending a multi-day rebound following its March 2026 IPO and recent strength in reported fiscal 2026 revenue.
- Shares have climbed sharply since July 10 as investors continue to digest the company's standalone diabetes-tech story following its spin-off from Medtronic.
- The stock remains supported by positive sentiment surrounding its $560 million in IPO proceeds and recent financial performance, despite a lack of fresh headlines this morning.